ID   7.159.2
AC   CVCL_B0L4
SY   50-002-7.159.2 HSFM; MEDI-573
DR   ABCD; ABCD_AA677
DR   Wikidata; Q108819731
RX   Patent=US9796779;
RX   PubMed=21245093;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7424.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma is tested as a potential therapeutic antibody with antineoplastic activity under the name dusigitumab.
CC   Monoclonal antibody isotype: IgG2, lambda.
CC   Monoclonal antibody target: UniProtKB; P05019; Human IGF1.
CC   Monoclonal antibody target: UniProtKB; P01344; Human IGF2.
CC   Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 23-09-21; Last updated: 02-05-24; Version: 6
//
RX   PubMed=21245093; DOI=10.1158/0008-5472.CAN-10-2274;
RA   Gao, Jin
RA   Chesebrough, Jon W.
RA   Cartlidge, Susan Ann
RA   Ricketts, Sally-Ann
RA   Incognito, Leonard S.
RA   Veldman-Jones, Margaret
RA   Blakey, David Charles
RA   Tabrizi, Mohammad
RA   Jallal, Bahija
RA   Trail, Pamela A.
RA   Coats, Steven
RA   Bosslet, Klaus
RA   Chang, Yong S.
RT   "Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF
RT   signaling and tumor growth.";
RL   Cancer Res. 71:1029-1040(2011).
//
RX   Patent=US9796779;
RA   Raeber, Olivia
RA   Gazit-Bornstein, Gadi
RA   Yang, Xiao-Dong
RA   Cartlidge, Susan Ann
RA   Tonge, David William
RT   "Binding proteins specific for insulin-like growth factors and uses
RT   thereof.";
RL   Patent number US9796779, 24-Oct-2017.
//